Business · Companies · 8 hrs ago
South Korea’s Zacubo Records First Monthly Prescription Sales Above 10 Billion Won
Zacubo had 10.3 billion won in outpatient prescription sales in October, its first month above 10 billion won.
The drug is made by South Korean pharmaceutical company Jeil Pharmaceutical and was launched in 2024.
It belongs to the P-CAB class of acid-reducing medicines, which is competing with older PPI treatments.
P-CAB sales in South Korea are expected to exceed 400 billion won this year, up from about 100 billion won in 2021.
Zacubo has been competing with K-Cab and Fexuclue, while Jeil has added a tablet that dissolves in the mouth and is testing expanded uses.
More competitors are expected to intensify the market battle: Daewon Pharmaceutical plans to seek approval for padoprazan this year, and Takeda is preparing to launch vonoprazan in South Korea.
South Korean drugmaker Jeil Pharmaceutical said Zacubo recorded 10.3 billion won in outpatient prescription sales in October, its first month above 10 billion won.
The figure was based on data from market research firm Ubist, cited by Jeil on Nov. 10.
Zacubo was developed by Jeil subsidiary Onconic Therapeutics and launched in 2024.
Jeil and Dong-A ST have conducted sales and marketing for the drug, and an orally disintegrating tablet was added in January.
Competition in South Korea’s P-CAB stomach-acid treatment market is expected to intensify as new products enter.
- Who
- Jeil Pharmaceutical said its drug Zacubo reached the milestone.
- What
- Zacubo recorded outpatient prescription sales of 10.3 billion won in October, its first month above 10 billion won.
- When
- October 2026; Jeil reported the figure on Nov. 10.
- Where
- South Korea.
- Why
- Not stated.
This story does not have two clearly opposing sides.
Zacubo, developed by Jeil subsidiary Onconic Therapeutics, was launched.
Jeil introduced an orally disintegrating tablet of Zacubo.
Zacubo’s outpatient prescription sales reached 10.3 billion won.
Jeil reported the October sales figure, citing Ubist data.
- October outpatient prescription sales
- 10.3 billion won
- First monthly sales above
- 10 billion won
- Drug developer
- Onconic Therapeutics, a Jeil Pharmaceutical subsidiary
- Launch year
- 2024
- Additional formulation
- Orally disintegrating tablet introduced in January